Advances in the treatment of Kawasaki disease

被引:14
作者
Dominguez, Samuel R. [1 ]
Anderson, Marsha S. [1 ]
机构
[1] Univ Colorado, Sch Med, Childrens Hosp Colorado, Dept Pediat,Sect Infect Dis, Aurora, CO USA
关键词
infliximab; IVIG resistant; Kawasaki disease; steroids; therapy; CORONARY-ARTERY ABNORMALITIES; INTRAVENOUS GAMMA-GLOBULIN; T-CELL-ACTIVATION; INFLIXIMAB TREATMENT; RANDOMIZED-TRIAL; PLASMA-EXCHANGE; RISK-FACTORS; CORTICOSTEROID-THERAPY; INITIAL TREATMENT; CHINESE POPULATION;
D O I
10.1097/MOP.0b013e32835c1122
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Purpose of review Intravenous immunoglobulin (IVIG) and aspirin is the standard initial therapy in the treatment of Kawasaki disease. Some patients have persistent or recrudescent fever despite this therapy. Although there is no conclusive body of evidence defining the best second and third-line therapies for Kawasaki patients, there have been several recent studies published describing the results of these therapies. Recent findings This review summarizes the current recommendations for the initial therapy and describes the second and third-line therapies studied in Japan and the United States. A recent study in a Japanese population of Kawasaki disease patients at high risk for IVIG resistance found that the group receiving steroids, in addition to IVIG and aspirin, had fewer coronary artery abnormalities than the group receiving IVIG and aspirin alone. Small studies of etanercept and infliximab have showed these TNF-alpha blockers to be well tolerated and effective in the resolution of fever. Summary Although most practitioners in the USA use IVIG as a second-line therapy for those Kawasaki disease patients who have persistent or recrudescent fever, promising new therapies are under study. Infliximab and steroids are currently the two agents that have been most studied. However, larger studies and studies in genetically diverse populations are needed.
引用
收藏
页码:103 / 109
页数:7
相关论文
共 68 条
[1]  
Ahn S Y, 2005, Scand J Rheumatol, V34, P136
[2]  
Athappan G, 2009, CARDIOVASC J AFR, V20, P233
[3]   A predictive instrument for coronary artery aneurysms in Kawasaki disease [J].
Beiser, AS ;
Takahashi, M ;
Baker, AL ;
Sundel, RP ;
Newburger, JW .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (09) :1116-1120
[4]   Kawasaki syndrome and risk factors for coronary artery abnormalities - United States, 1994-2003 [J].
Belay, ED ;
Maddox, RA ;
Holman, RC ;
Curns, AT ;
Ballah, K ;
Schonberger, LB .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (03) :245-249
[5]   T cell activation profiles in Kawasaki syndrome [J].
Brogan, P. A. ;
Shah, V. ;
Clarke, L. A. ;
Dillon, M. J. ;
Klein, N. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2008, 151 (02) :267-274
[6]   CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease [J].
Brown, TJ ;
Crawford, SE ;
Cornwall, ML ;
Garcia, F ;
Shulman, ST ;
Rowley, AH .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (07) :940-943
[7]   Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease [J].
Burns, Jane C. ;
Best, Brookie M. ;
Mejias, Asuncion ;
Mahony, Lynn ;
Fixler, David E. ;
Jafri, Hasan S. ;
Melish, Marian E. ;
Jackson, Mary Anne ;
Asmar, Basim I. ;
Lang, David J. ;
Connor, James D. ;
Capparelli, Edmund V. ;
Keen, Monica L. ;
Mamun, Khalid ;
Keenan, Gregory F. ;
Ramilo, Octavio .
JOURNAL OF PEDIATRICS, 2008, 153 (06) :833-838
[8]   Infliximab treatment for refractory Kawasaki syndrome [J].
Burns, JC ;
Mason, WH ;
Hauger, SB ;
Janai, H ;
Bastian, JF ;
Wohrley, JD ;
Balfour, I ;
Shen, CA ;
Michel, ED ;
Shulman, ST ;
Melish, ME .
JOURNAL OF PEDIATRICS, 2005, 146 (05) :662-667
[9]   Kawasaki syndrome [J].
Burns, JC ;
Glodé, MP .
LANCET, 2004, 364 (9433) :533-544
[10]   ITPKC gene SNP rs28493229 and Kawasaki disease in Taiwanese children [J].
Chi, Hsin ;
Huang, Fu-Yuan ;
Chen, Ming-Ren ;
Chiu, Nan-Chang ;
Lee, Hung-Chang ;
Lin, Shuan-Pei ;
Chen, Wei-Fang ;
Lin, Chong-Ling ;
Chan, Hui-Wen ;
Liu, Hsin-Fu ;
Huang, Li-Min ;
Lee, Yann-Jinn .
HUMAN MOLECULAR GENETICS, 2010, 19 (06) :1147-1151